HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Venetoclax"

A phase 2 trial of the investigational medicine Venetoclax met its primary endpoint ( overall response rates ) in patients with relapsed / refractory or previously untreated chronic lymphocytic leukem ...


Data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months in previously untreated patients with chronic lymphocyti ...


The treatment of relapsed or refractory diffuse large B-cell lymphoma ( R/R DLBCL ) remains challenging. Atezolizumab ( Tecentriq ) and Obinutuzumab ( Gazyvaro ) are monoclonal antibodies acting res ...


Based on in vitro studies, Polatuzumab vedotin + Obinutuzumab + Venetoclax ( Pola-G-Ven )may have significant anti-tumor activity in relapsed / refractory follicular lymphoma ( R/R FL ). Researchers ...


Current available therapies for patients with acute myeloid leukemia ( AML ) who are ineligible for intensive therapy yield limited responses with poor survival. Venetoclax ( Venclyxto ) is a sele ...


Venetoclax ( Venclexta ) in newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a series of trials including two phase 3 trials, VIALE-A ( M15-656 ) an ...


Polatuzumab vedotin ( Polivy ) combined with Rituximab ( MabThera ) has demonstrated activity and tolerability in a phase II trial of patients with relapsed / refractory ( R/R ) diffuse large B-cell l ...